In today’s highly regulated healthcare environment, medical device regulatory compliance is essential for protecting patients, maintaining product quality, building customer trust, and reducing regulatory risks. For medical device manufacturers, importers, distributors, and other stakeholders operating in India, understanding and complying with the Medical Devices Rules, 2017 (MDR 2017) and other applicable Indian requirements is a critical business responsibility.
India’s medical device regulatory framework establishes requirements for device classification, licensing, manufacturing, quality management, labelling, safety, performance, and post-market surveillance. However, navigating these requirements can be challenging. Incomplete technical documentation, incorrect risk classification, licensing errors, inadequate quality management systems, and ineffective adverse-event reporting can lead to regulatory queries, product delays, compliance gaps, and potential patient-safety concerns.
At MDR Consultants, we understand that effective regulatory compliance requires more than obtaining a licence. It involves a structured, risk-based approach that integrates regulatory planning, controlled documentation, quality assurance, and continuous post-market monitoring.
Medical devices in India are regulated primarily under the Medical Devices Rules, 2017, framed under the Drugs and Cosmetics Act, 1940, together with applicable amendments, notifications, and other relevant legal requirements.
The Central Drugs Standard Control Organisation (CDSCO) is India’s national regulatory authority for medical devices. Depending on the device, classification, and regulatory activity, licensing responsibilities may rest with the Central Licensing Authority or the relevant State or Union Territory Licensing Authority.
Medical devices are classified into four risk categories:
The applicable regulatory requirements depend on factors such as the device’s intended purpose, risk classification, manufacturing or import activity, sterile or measuring status, and any specific exemptions or conditions provided under the applicable rules.
For example, certain Class A non-sterile and non-measuring devices may qualify for an exemption from the licensing requirements, subject to the applicable registration and other regulatory conditions. Organizations should not assume that all Class A devices are exempt.
Regulatory compliance also extends beyond initial licensing. Manufacturers and importers must address applicable requirements relating to technical documentation, quality management, labelling, risk management, complaint handling, vigilance, and post-market reporting.
Understanding the regulatory pathway applicable to each device is the first step toward avoiding preventable compliance mistakes.
Technical documentation provides evidence that a medical device meets the applicable safety, quality, and performance requirements. Incomplete, inconsistent, or outdated records can complicate licensing applications, regulatory reviews, and inspections.
Depending on the device and applicable regulatory pathway, documentation may include:
Establish a controlled technical documentation system aligned with the applicable provisions of the Medical Devices Rules, 2017, and relevant regulatory guidance.
Assign document owners, maintain revision histories, and establish approval procedures. Introduce formal change control to ensure that modifications to the device, intended purpose, manufacturing process, or regulatory requirements trigger a review of affected documentation.
Before submitting an application, conducting an internal audit, or responding to a regulatory query, perform a structured documentation review to confirm completeness, consistency, traceability, and accuracy.
Medical devices must have appropriate evidence supporting their safety and performance. The type and extent of evidence required depend on the device’s intended purpose, risk classification, technology, novelty, and applicable regulatory provisions.
A common mistake is assuming that existing literature, overseas approval, or limited performance testing will automatically satisfy Indian regulatory requirements.
Evidence may be insufficient if it does not adequately support the device’s intended use, claimed performance, target population, or specific technology.
Develop an evidence-generation strategy early in the product lifecycle.
Identify the applicable regulatory requirements and determine whether existing evidence is adequate. Depending on the device, this may involve bench testing, biocompatibility assessment, electrical safety and electromagnetic compatibility testing, software verification and validation, clinical evaluation, or performance evaluation.
Where required, assess whether a clinical investigation or additional performance studies are necessary under the applicable Indian rules and guidance.
Ensure that claims made in product labelling, promotional materials, instructions for use, and technical documentation are supported by appropriate evidence.
For imported devices, evaluate the relevance and adequacy of overseas evidence rather than assuming that foreign-market approval automatically fulfils every Indian requirement.
Risk classification determines the applicable regulatory pathway and influences licensing requirements, technical documentation, quality management expectations, and regulatory oversight.
Incorrect classification can lead to inappropriate applications, additional regulatory queries, rework, and delays in market entry.
Classification errors may arise when organizations misunderstand the device’s intended purpose, overlook special classification rules, rely on outdated information, or apply a foreign classification without assessing the Indian requirements.
Software-based medical devices and in vitro diagnostic medical devices (IVDs) may require particular attention because their classification depends on specific regulatory criteria.
Review the applicable classification provisions under the Medical Devices Rules, 2017, and the current CDSCO risk-classification information for the specific device.
Document the device’s intended purpose, relevant characteristics, classification rationale, and supporting regulatory references.
CDSCO introduced an online application facility for obtaining risk classification of medical devices other than IVDs from 27 November 2025 and for IVDs from 18 February 2026. Organizations should check the current classification information and application instructions when a device’s classification is unclear or is not adequately covered by the published lists.
Do not rely exclusively on classifications assigned under the European Union Medical Device Regulation, United States FDA requirements, or other international frameworks. These may provide useful supporting information, but the Indian classification must be established under the applicable Indian rules.
Also verify whether a device falls within a specific exemption, registration pathway, or additional regulatory requirement before preparing the licensing application.
Risk management is a lifecycle activity intended to identify, evaluate, control, and monitor risks associated with a medical device.
A common mistake is treating risk management as a one-time exercise completed during product development or immediately before a regulatory submission.
Other weaknesses include incomplete hazard identification, inadequate risk-control measures, poor traceability between identified risks and verification activities, and failure to reassess risks following complaints or product changes.
Implement a documented risk management process appropriate to the device and aligned with applicable Indian regulatory requirements and relevant standards, such as ISO 14971 where appropriate.
The process should address:
Integrate risk management with design controls, supplier management, complaint handling, change control, corrective and preventive action, and post-market surveillance.
New complaints, adverse events, changes in materials, software updates, and emerging safety information should trigger an assessment of whether existing risk evaluations and controls remain adequate.
Regulatory responsibilities continue after a medical device has been licensed and placed on the market.
Post-market surveillance helps organizations identify emerging safety concerns, performance problems, recurring complaints, and opportunities for product improvement.
A common mistake is treating post-market surveillance as a documentation exercise rather than an ongoing process for collecting and evaluating real-world information.
Establish a post-market surveillance process appropriate to the device and its applicable regulatory obligations.
Define the information to be collected, review frequency, responsible personnel, evaluation methods, escalation criteria, and required actions.
Depending on the device and applicable requirements, post-market activities may include:
Determine whether a post-market surveillance report, periodic safety update report (PSUR), or other reporting obligation applies to the specific device, licence, and applicable CDSCO instructions.
CDSCO has issued instructions concerning the submission of medical device and IVD PSURs through its online medical device portal. Organizations should confirm the applicable reporting schedule, submission procedure, and product-specific obligations rather than assuming that the same requirements apply to every device.
Post-market findings should feed into risk management, product improvements, technical documentation updates, and decisions concerning field safety corrective actions.
Failure to identify, investigate, escalate, or report medical device-related adverse events can compromise patient safety and create regulatory compliance risks.
Organizations may lack clear procedures for assessing whether an incident is reportable, collecting relevant information, evaluating causality, investigating the event, and implementing appropriate corrective action.
India’s Materiovigilance Programme of India (MvPI) supports the monitoring of medical device-related adverse events. CDSCO has also issued a circular concerning adverse-event reporting by medical device licence holders under MvPI.
Establish a documented vigilance and adverse-event reporting procedure that defines how potential incidents are received, assessed, investigated, escalated, and reported.
The procedure should address:
Train employees, distributors, and customer-facing teams to recognize potential safety issues and communicate them promptly.
Do not assume that every complaint is a reportable adverse event or that every event can be closed as a routine complaint. Each case should be assessed according to the applicable regulatory criteria and reporting obligations.
Where required, initiate corrective and preventive action (CAPA), communicate relevant safety information, assess the need for a field safety corrective action, and maintain appropriate investigation records.
Labelling, packaging, and instructions for use provide essential information about a medical device, including its intended purpose, safe use, warnings, traceability, and manufacturer or importer details.
Missing, inaccurate, or inconsistent information can result in non-compliance and may affect safe product use.
Common mistakes include:
Review labelling against the applicable requirements of the Medical Devices Rules, 2017, including Rule 44 and the relevant provisions of the Sixth Schedule, as applicable to the device.
Assess other applicable requirements concerning packaging, legal metrology, and market-specific information where relevant.
Verify that the label, packaging, instructions for use, and regulatory documentation consistently identify the device and accurately communicate its intended purpose, safe use, warnings, precautions, and other required particulars.
For imported devices, confirm that the required Indian-market information and importer particulars are addressed.
Where sterilization activities and related labelling requirements apply, review the relevant provisions and amendments to the Medical Devices Rules, 2017, including the applicable requirements introduced in 2026.
Introduce formal review and approval procedures for label changes. Ensure that approved revisions are implemented consistently across product versions, packaging materials, instructions for use, and associated technical documentation.
A quality management system (QMS) helps medical device organizations establish consistent processes for product quality, regulatory compliance, risk control, and continual improvement.
A common mistake is creating procedures primarily to prepare for inspections without ensuring that employees consistently follow them in day-to-day operations.
Other issues include outdated procedures, incomplete training records, ineffective CAPA, weak supplier controls, and insufficient management oversight.
Maintain a QMS that meets the applicable requirements of the Medical Devices Rules, 2017, including relevant provisions of the Fifth Schedule, as applicable to the device and activity.
Relevant processes may include:
ISO 13485 is widely used for medical device quality management and may support an organization’s compliance approach. However, certification alone does not automatically establish compliance with every applicable Indian regulatory requirement.
Organizations should also assess the effect of relevant amendments to the Medical Devices Rules, 2017. Regulatory changes published in August 2026 include amendments concerning quality management system requirements in specified provisions and recognition of European Union countries under a provision relating to import licensing. The applicability of these provisions should be assessed against the device, activity, and relevant rule.
Conduct periodic internal audits, evaluate recurring quality issues, maintain training records, and ensure that management reviews result in documented decisions and effective follow-up actions.
Medical device compliance often depends on activities performed by external suppliers, contract manufacturers, importers, and distributors.
Weak oversight can affect product quality, traceability, technical documentation, complaint investigation, and the ability to respond to safety concerns.
Organizations may also misunderstand the regulatory responsibilities associated with their role in the supply chain.
Establish risk-based supplier qualification, approval, and monitoring procedures.
Define quality and regulatory expectations in supplier agreements. Verify relevant supplier documentation, evaluate performance, and maintain records of supplier assessments and follow-up actions.
For imported devices, confirm that the applicable import licence or other required regulatory authorization is in place and that the device and relevant manufacturing arrangements are appropriately covered.
Maintain the required supporting documentation, including manufacturer information, product details, and applicable quality and regulatory records.
For domestic manufacturing, verify that the relevant manufacturing licence, site, device category, and manufacturing activity are covered by the applicable authorization.
Establish traceability and communication channels that allow complaints, product changes, safety concerns, and regulatory requests to be handled promptly.
Outsourcing an activity does not automatically eliminate an organization's own regulatory responsibilities. Responsibilities should be clearly allocated, documented, and periodically reviewed.
India’s medical device regulatory framework evolves through amendments, notifications, classification updates, regulatory circulars, and changes to application and reporting processes.
Organizations that rely on outdated information may submit applications using superseded requirements, miss applicable obligations, or fail to update their quality systems and technical documentation.
Establish a formal regulatory intelligence process to identify relevant changes and assess their impact on products, licences, documentation, manufacturing activities, and post-market responsibilities.
Assign responsibility for monitoring:
Maintain a regulatory change register documenting the change, its applicability, the impact assessment, assigned responsibilities, implementation deadlines, and closure evidence.
Distinguish between draft notifications and final notifications. A draft proposal should not be treated as an effective legal requirement unless and until it is finalized and becomes applicable.
Where a final amendment has been issued, determine its effective date, scope, transitional provisions, and impact on existing licences or products.
Include regulatory change assessments in internal audits and management reviews to ensure that new requirements are translated into practical actions.
Organizations can use the following checklist as an initial internal review tool.
This checklist is a starting point, not a substitute for a device-specific regulatory assessment. Actual requirements depend on the device, classification, intended purpose, manufacturing or import activity, applicable exemptions, licence conditions, and current legal provisions.
Navigating India’s medical device regulatory requirements can be resource-intensive, particularly for organizations introducing new devices, importing products, expanding manufacturing operations, or strengthening their quality management systems.
MDR Consultants can support organizations in developing a structured regulatory compliance strategy by helping identify potential gaps, organize documentation, strengthen quality processes, and improve readiness for regulatory reviews.
Depending on your requirements, support may include:
A tailored regulatory approach helps organizations prioritize significant compliance gaps, allocate resources effectively, and improve long-term regulatory readiness.
Medical device regulatory compliance in India requires more than obtaining a licence or preparing documentation for an inspection. It depends on a coordinated system that integrates classification, licensing, technical documentation, appropriate evidence, risk management, quality assurance, labelling, and post-market monitoring.
Common mistakes—including incorrect classification, incomplete technical documentation, inadequate clinical or performance evidence, ineffective quality management, and missed adverse-event reporting obligations—can often be reduced through early planning, clear accountability, regular reviews, and effective change management.
Organizations should periodically assess their compliance status against the latest applicable provisions of the Medical Devices Rules, 2017, relevant CDSCO notifications, and licence conditions. A proactive and well-documented compliance programme can support patient safety, improve regulatory readiness, and reduce avoidable licensing delays and operational disruptions.
MDR Consultants can help your organization identify potential compliance gaps and develop a practical roadmap for sustainable medical device regulatory compliance in India. Contact our team to discuss your regulatory challenges and determine the support best suited to your medical device business.
Last Updated : 15 Oct 2026
The Brand That Promises To Turn Your Business Around!
MDR Consultants excels in guiding medical device companies through global regulatory approvals with tailored solutions, clear communication, and efficient delivery. Their mission-driven approach fosters innovation, compliance, and long-term partnerships built on trust and excellence.
As I observed this company maintains a very good and cooperative environment. "MDR" consultancy is equipped with all modern amenities. They guide you the best. I highly recommend this firm. The entire team is very courteous and helpful. Highly Professional team and the owner is very skilled and humble.
Outstanding expertise! They streamlined our regulatory process, saving us immense time and stress. A truly invaluable partner for medical device compliance.
MDR Consultants have been a reliable partner for our CDSCO registration needs. Their efficient processes and in-depth knowledge of the regulations saved us significant time and resources. We are confident about the quality of their services and their commitment to client satisfaction.
MDR team has consistently delivered quality work, meeting deadlines and exceeding our expectations. We really recommend MDR for regulatory support
My experience with MDR consultants is wonderful. They have in-depth and vast knowledge about their work. They have the team of incredible people. Their commitment towards the client is highly appreciable. I highly recommend to have their services.
MDR IS THE BEST SOLUTION FOR MEDICAL DEVICES CONSULTANCIE THEY PROVIDE ALL THE SOLUTIONS AND PROPER GUIDANCE.AND DELIVER THEIR SERVICES ON TIME .
MDR team has consistently delivered high quality work, meeting deadlines and exceeding our expectations.
It was really a nice experience working with MDR consultancy.They guide you properly with their tranparent work ethics.Honestly MDR consultancy helped me a lot in growing my business.
A very friendly bunch of efficient employees in the team of MDR.A very professional approach towards their job and all my work was done hassle free with least follow up from my side.Keep up great work team MDR!!!!👍👍
The services are top notch , highly recommend for Mr Ashish
Best regulatory services..for medical devices…best in the business
Have a rich experience in the field of consultancy.
Extremely helpful and responsive
Very good experience
Good Services
Appreciable work.
True consultant
Medical Device Regulatory Consultants
37-38, 1st Floor, Near Makhan Bhog, G.T. Road,
Kundli Industrial Area, Delhi NCR, 131028